Polaryx Therapeutics, Inc. Common Stock (PLYX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Polaryx Therapeutics, Inc. Common Stock stock (PLYX) is currently trading at $6.28. Analyst consensus price target for PLYX is $10.00. WallStSmart rates PLYX as Sell.
- PLYX PE ratio analysis and historical PE chart
- PLYX PS ratio (Price-to-Sales) history and trend
- PLYX intrinsic value — DCF, Graham Number, EPV models
- PLYX stock price prediction 2025 2026 2027 2028 2029 2030
- PLYX fair value vs current price
- PLYX insider transactions and insider buying
- Is PLYX undervalued or overvalued?
- Polaryx Therapeutics, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- PLYX Piotroski F-Score and Altman Z-Score
- PLYX analyst price target and Smart Rating
Polaryx Therapeutics, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Polaryx Therapeutics, Inc. Common Stock (PLYX) · 3 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around price/book and institutional own.. Significant fundamental concerns warrant caution or avoidance.
Polaryx Therapeutics, Inc. Common Stock (PLYX) Key Strengths (0)
Supporting Valuation Data
Polaryx Therapeutics, Inc. Common Stock (PLYX) Areas to Watch (3)
Very expensive at 49.6x book value
Very low institutional interest at 0.00%
Small-cap company with higher risk but more growth potential
Polaryx Therapeutics, Inc. Common Stock (PLYX) Detailed Analysis Report
Overall Assessment
This company scores 8/100 in our Smart Analysis, earning a F grade. Out of 3 metrics analyzed, 0 register as strengths (avg 0/10) while 3 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Price/Book, Institutional Own., Market Cap. Some valuation metrics including Price/Book (49.57) suggest expensive pricing.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, overall profitability trends. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Price/Book and Institutional Own. are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PLYX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
Insider Transactions
Loading insider activity...
About Polaryx Therapeutics, Inc. Common Stock(PLYX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. The company is headquartered in Paramus, New Jersey.